- ►diabetesjournals.org KK Koh, MJ Quon, SH Han, WJ Chung, JY Ahn, … - Diabetes care, 2006 - Am Diabetes Assoc RESULTS—Fenofibrate, combined therapy, or candesartan therapy significantly
reduced blood pressure. However, combined therapy significantly reduced blood
pressure more than fenofibrate or candesartan alone (P < 0.001 by ANOVA). ... Cited by 31 - Related articles - BL Direct - All 8 versions
SH Han, KK Koh, MJ Quon, Y Lee, EK Shin - Atherosclerosis, 2007 - Elsevier The proinflammatory mediator CD40 ligand plays an important role in
atherogenesis. Biological mechanisms underlying statin and angiotensin II type 1
receptor blocker therapies differ. Therefore, we compared the effects of ... Cited by 10 - Related articles - All 36 versions
- ►ahajournals.org KK Koh, MJ Quon, SH Han, JY Ahn, DK Jin, … - Hypertension, 2005 - Am Heart Assoc Mechanisms underlying biological effects of statin and angiotensin-converting
enzyme inhibitor therapies differ. Therefore, we compared vascular and metabolic
responses to these therapies either alone or in combination in patients ... Cited by 105 - Related articles - All 10 versions
Y Asano, J Kim, A Ogai, S Takashima, Y … - Biochemical and Biophysical Research …, 2003 - Elsevier Since amlodipine, a long-acting Ca channel blocker, increases both NO and
adenosine production in canine hearts, we investigated that amlodipine activates
both ecto-5 ′ -nucleotidase responsible for adenosine production and NO ... Cited by 13 - Related articles - All 5 versions
K Kon Koh, MJ Quon, SH Han, WJ Chung, Y … - International journal of cardiology, 2006 - Elsevier Candesartan therapy significantly lowered both systolic and diastolic blood
pressure. Compared with placebo, candesartan therapy significantly lowered
plasma hsCRP levels relative to baseline measurements from 1.10 to 0.70 ... Cited by 57 - Related articles - All 16 versions
- ►ahajournals.org KK Koh, MJ Quon, SH Han, WJ Chung, JY Ahn … - Circulation, 2004 - Am Heart Assoc Methods and Results— This was a randomized, double-blind, placebo-controlled
crossover trial with 3 treatment arms (each 2 months) and 2 washout periods
(each 2 months). Forty-seven hypertensive, hypercholesterolemic patients ... Cited by 158 - Related articles - All 12 versions
S Watanabe, T Okura, M Kurata, J Irita, S … - Clinical therapeutics, 2006 - Elsevier All 40 participants completed both 3-month treatment periods. Study patients
were primarily male (52.5%) with a mean (SD) age of 63.8 (10.6) years and a mean
body weight of 60.7 (10.8) kg. Patients with EHT and diabetes mellitus (n = ... Cited by 22 - Related articles - All 3 versions
K Kon Koh, J Yeal Ahn, S Hwan Han, D Kyu … - Atherosclerosis, 2004 - Elsevier We investigated the effects of fenofibrate, peroxisome proliferator-activated
receptors (PPARs) agonist, on endothelial function in patients with
hypertriglyceridemia. We administered placebo or fenofibrate 200 mg daily ... Cited by 42 - Related articles - All 6 versions
- ►endojournals.org TS Hermann, W Li, H Dominguez, N Ihlemann … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Methods: Twenty-four type 2 diabetic subjects were randomized to receive 2
months of quinapril 20 mg daily or no treatment in an open parallel study.
Endothelium-dependent and -independent vasodilation was studied during ... Cited by 32 - Related articles - BL Direct - All 4 versions
- ►onlinejacc.org SH Han, MJ Quon, J Kim, KK Koh - Journal of the American College of Cardiology, 2007 - Elsevier Adiponectin is a protein secreted specifically by adipose cells that may couple
regulation of insulin sensitivity with energy metabolism and serve to link
obesity with insulin resistance. Obesity-related disorders including the ... Cited by 92 - Related articles - BL Direct - All 20 versions
